Erden Atilla1, Pinar Ataca Atilla1, Sinem Civriz Bozdağ1, Taner Demirer2. 1. Department of Hematology, Ankara University Medical School, Cebeci, 06590, Ankara, Turkey. 2. Department of Hematology, Ankara University Medical School, Cebeci, 06590, Ankara, Turkey. demirer@medicine.ankara.edu.tr.
Abstract
BACKGROUND: Allogeneic hematopoietic stem cell transplantation from haploidentical donor is a feasible option for patients with hematological diseases who lack a suitable HLA-matched donor, but viral and fungal infections are still the most common causes of morbidity and mortality in haploidentical transplantation setting because of delayed immune reconstitution, increased risk of graft vs host disease (GvHD) or systemic steroid use. Therefore, this review will focus on the infectious complications after haploidentical hematopoietic stem cell transplantation (HSCT). MATERIALS AND METHODS: Electronic publications were searched until February 2017 throughout databases, including Pubmed, Cochrane, and Embase. The following keywords were used 'haploidentical transplantation', 'infection', 'T cell replete', and 'T cell deplete'. RESULTS: An increased incidence of bacterial, fungal, or viral infections is detected in haplo-HSCT compared to related, unrelated, or cord blood transplantations. Neutropenia and use of systemic steroid for GvHD and delayed immune reconstitution are important risk factors for infection after haplo-HSCT. CONCLUSION: A shift towards T cell repletes haplo-HSCT with post-transplant cyclophosphamide (CY) for GvHD has been emerged in recent years, in which the incidence of viral and fungal infections is detected to be lower. Prophylaxis and pre-emptive treatment strategies should be applied according to patient status.
BACKGROUND: Allogeneic hematopoietic stem cell transplantation from haploidentical donor is a feasible option for patients with hematological diseases who lack a suitable HLA-matched donor, but viral and fungal infections are still the most common causes of morbidity and mortality in haploidentical transplantation setting because of delayed immune reconstitution, increased risk of graft vs host disease (GvHD) or systemic steroid use. Therefore, this review will focus on the infectious complications after haploidentical hematopoietic stem cell transplantation (HSCT). MATERIALS AND METHODS: Electronic publications were searched until February 2017 throughout databases, including Pubmed, Cochrane, and Embase. The following keywords were used 'haploidentical transplantation', 'infection', 'T cell replete', and 'T cell deplete'. RESULTS: An increased incidence of bacterial, fungal, or viral infections is detected in haplo-HSCT compared to related, unrelated, or cord blood transplantations. Neutropenia and use of systemic steroid for GvHD and delayed immune reconstitution are important risk factors for infection after haplo-HSCT. CONCLUSION: A shift towards T cell repletes haplo-HSCT with post-transplant cyclophosphamide (CY) for GvHD has been emerged in recent years, in which the incidence of viral and fungal infections is detected to be lower. Prophylaxis and pre-emptive treatment strategies should be applied according to patient status.
Authors: Michael Boeckh; W Garrett Nichols; Roy F Chemaly; Genovefa A Papanicolaou; John R Wingard; Hu Xie; Karen L Syrjala; Mary E D Flowers; Terry Stevens-Ayers; Keith R Jerome; Wendy Leisenring Journal: Ann Intern Med Date: 2015-01-06 Impact factor: 25.391
Authors: U De Giorgi; T Demirer; H Wandt; C Taverna; W Siegert; M Bornhauser; T Kozak; G Papiani; M Ballardini; G Rosti Journal: Ann Oncol Date: 2005-01 Impact factor: 32.976
Authors: L A Holmberg; T Demirer; S Rowley; C D Buckner; G Goodman; R Maziarz; J Klarnet; N Zuckerman; G Harrer; R McCloskey; R Gersh; R Goldberg; W Nichols; A Jacobs; P Weiden; P Montgomery; S Rivkin; F R Appelbaum; W I Bensinger Journal: Bone Marrow Transplant Date: 1998-10 Impact factor: 5.483
Authors: N T Ueno; J D Rizzo; T Demirer; Y C Cheng; U Hegenbart; M-J Zhang; M Bregni; A Carella; D Blaise; A Bashey; J D Bitran; B J Bolwell; G J Elfenbein; K K Fields; C O Freytes; R P Gale; H M Lazarus; R E Champlin; P J Stiff; D Niederwieser Journal: Bone Marrow Transplant Date: 2007-12-17 Impact factor: 5.483
Authors: Ashley Leak Bryant; Erin Coffman; Brett Phillips; Xianming Tan; Elizabeth Bullard; Rachel Hirschey; Joshua Bradley; Antonia V Bennett; Angela M Stover; Lixin Song; Thomas C Shea; William A Wood Journal: Support Care Cancer Date: 2019-06-20 Impact factor: 3.603
Authors: Ghada ElGohary; Riad El Fakih; Regis de Latour; Antonio Risitano; Judith Marsh; Hubert Schrezenmeier; Eliane Gluckman; Britta Höchsmann; Filomena Pierri; Constantijn Halkes; Hazzaa Alzahrani; Josu De la Fuente; Simone Cesaro; Ali Alahmari; Syed Osman Ahmed; Jakob Passweg; Carlo Dufour; Andrea Bacigalupo; Mahmoud Aljurf Journal: Bone Marrow Transplant Date: 2020-04-28 Impact factor: 5.483
Authors: Dietlinde Wolf; Cameron S Bader; Henry Barreras; Sabrina Copsel; Brent J Pfeiffer; Casey O Lightbourn; Norman H Altman; Krishna V Komanduri; Robert B Levy Journal: JCI Insight Date: 2018-10-18